PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment

被引:244
作者
Kemppainen, N. M.
Aalto, S.
Wilson, I. A.
Nagren, K.
Helin, S.
Bruck, A.
Oikonen, V.
Kailajarvi, M.
Scheinin, M.
Viitanen, M.
Parkkola, R.
Rinne, J. O.
机构
[1] Univ Turku, Turku PET Ctr, Dept Pharmacol, FIN-20521 Turku, Finland
[2] Univ Turku, CRST, FIN-20521 Turku, Finland
[3] Abo Akad Univ, Dept Psychol, Turku, Finland
[4] Turku Univ, Cent Hosp, Dept Clin Radiol, Turku, Finland
[5] Turku City Hosp, Turku, Finland
[6] Turku Imanet, Turku, Finland
[7] Karolinska Inst, Stockholm, Sweden
关键词
D O I
10.1212/01.wnl.0000260969.94695.56
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Patients with mild cognitive impairment (MCI) have increased risk to develop Alzheimer disease (AD). In AD increased brain amyloid burden has been demonstrated in vivo with PET using N-methyl-[C-11]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole ([C-11]PIB) as a tracer. Objective: To investigate whether patients with amnestic MCI would show increased [C-11]PIB uptake, indicating early AD process. Methods: We studied 13 patients with amnestic MCI and 14 control subjects with PET using [C-11]PIB as tracer. Parametric images were computed by calculating the region-to-cerebellum ratio in each voxel over 60 to 90 minutes. Group differences in [C-11]PIB uptake were analyzed with statistical parametric mapping (SPM) and automated region-of-interest (ROI) analysis. Results: The SPM analysis showed that patients with MCI had significantly higher [C-11]PIB uptake vs control subjects in the frontal, parietal, and lateral temporal cortices as well as in the posterior cingulate showing the most prominent differences. These results were supported by the automated ROI analysis in which MCI patients showed in comparison with healthy control subjects increased [C-11]PIB uptake in the frontal cortex (39% increase from the control mean, p < 0.01), the posterior cingulate (39%, p < 0.01), the parietal (31%, p < 0.01) and lateral temporal (28%, p < 0.001) cortices, putamen (17%, p < 0.05), and caudate (25%, p < 0.05). Individually, in the frontal cortex and posterior cingulate, 8 of 13 patients with MCI had [C-11]PIB uptake values above 2 SD from the control mean. MCI subjects having at least one APOE epsilon 4 allele tended to have higher [C-11]PIB uptake than MCI subjects without APOE epsilon 4. Conclusions: At group level the elevated N-methyl-[C-11]2-(4'-methylaminophenyl)- 6-hydroxybenzothiazole ([C-11]PIB) uptake in patients with mild cognitive impairment (MCI) resembled that seen in Alzheimer disease (AD). At the individual level, about half of the MCI patients had [C-11]PIB uptake in the AD range, suggestive of early AD process.
引用
收藏
页码:1603 / 1606
页数:4
相关论文
共 18 条
[1]
NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES [J].
BRAAK, H ;
BRAAK, E .
ACTA NEUROPATHOLOGICA, 1991, 82 (04) :239-259
[2]
Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease [J].
Brück, A ;
Aalto, S ;
Nurmi, E ;
Bergman, J ;
Rinne, JO .
NEUROBIOLOGY OF AGING, 2005, 26 (06) :891-898
[3]
Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory [J].
Buckner, RL ;
Snyder, AZ ;
Shannon, BJ ;
LaRossa, G ;
Sachs, R ;
Fotenos, AF ;
Sheline, YI ;
Klunk, WE ;
Mathis, CA ;
Morris, JC ;
Mintun, MA .
JOURNAL OF NEUROSCIENCE, 2005, 25 (34) :7709-7717
[4]
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans [J].
Fagan, AM ;
Mintun, MA ;
Mach, RH ;
Lee, SY ;
Dence, CS ;
Shah, AR ;
LaRossa, GN ;
Spinner, ML ;
Klunk, WE ;
Mathis, CA ;
DeKosky, ST ;
Morris, JC ;
Holtzman, DM .
ANNALS OF NEUROLOGY, 2006, 59 (03) :512-519
[5]
CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment [J].
Herukka, SK ;
Hallikainen, M ;
Soininen, H ;
Pirttilä, T .
NEUROLOGY, 2005, 64 (07) :1294-1297
[6]
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI [J].
Jack, CR ;
Shiung, MM ;
Weigand, SD ;
O'Brien, PC ;
Gunter, JL ;
Boeve, BF ;
Knopman, DS ;
Smith, GE ;
Ivnik, RJ ;
Tangalos, EG ;
Petersen, RC .
NEUROLOGY, 2005, 65 (08) :1227-1231
[7]
Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease [J].
Kemppainen, N. M. ;
Aalto, S. ;
Wilson, I. A. ;
Nagren, K. ;
Helin, S. ;
Bruck, A. ;
Oikonen, V. ;
Kailajarvi, M. ;
Scheinin, M. ;
Viitanen, M. ;
Parkkola, R. ;
Rinne, J. O. .
NEUROLOGY, 2006, 67 (09) :1575-1580
[8]
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B [J].
Klunk, WE ;
Engler, H ;
Nordberg, A ;
Wang, YM ;
Blomqvist, G ;
Holt, DP ;
Bergström, M ;
Savitcheva, I ;
Huang, GF ;
Estrada, S ;
Ausén, B ;
Debnath, ML ;
Barletta, J ;
Price, JC ;
Sandell, J ;
Lopresti, BJ ;
Wall, A ;
Koivisto, P ;
Antoni, G ;
Mathis, CA ;
Långström, B .
ANNALS OF NEUROLOGY, 2004, 55 (03) :306-319
[9]
Neuropathologic substrate of mild cognitive impairment [J].
Markesbery, WR ;
Schmitt, FA ;
Kryscio, RJ ;
Davis, DG ;
Smith, CD ;
Wekstein, DR .
ARCHIVES OF NEUROLOGY, 2006, 63 (01) :38-46
[10]
Assessment of spatial normalization of PET ligand images using ligand-specific templates [J].
Meyer, JH ;
Gunn, RN ;
Myers, R ;
Grasby, PM .
NEUROIMAGE, 1999, 9 (05) :545-553